|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIM2 |
Gene summary for TRIM2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIM2 | Gene ID | 23321 |
| Gene name | tripartite motif containing 2 | |
| Gene Alias | CMT2R | |
| Cytomap | 4q31.3 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q9C040 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23321 | TRIM2 | CA_HPV_1 | Human | Cervix | CC | 8.99e-09 | -2.78e-01 | 0.0264 |
| 23321 | TRIM2 | CA_HPV_3 | Human | Cervix | CC | 2.44e-02 | -2.31e-01 | 0.0414 |
| 23321 | TRIM2 | N_HPV_1 | Human | Cervix | N_HPV | 4.34e-05 | -2.58e-01 | 0.0079 |
| 23321 | TRIM2 | N_HPV_2 | Human | Cervix | N_HPV | 1.34e-02 | -2.46e-01 | -0.0131 |
| 23321 | TRIM2 | CCI_1 | Human | Cervix | CC | 4.97e-02 | 6.42e-01 | 0.528 |
| 23321 | TRIM2 | CCI_2 | Human | Cervix | CC | 9.64e-04 | 7.16e-01 | 0.5249 |
| 23321 | TRIM2 | H2 | Human | Cervix | HSIL_HPV | 5.94e-07 | 3.49e-01 | 0.0632 |
| 23321 | TRIM2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.73e-08 | -4.24e-01 | 0.0155 |
| 23321 | TRIM2 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.80e-19 | 8.02e-01 | -0.1954 |
| 23321 | TRIM2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.76e-03 | -5.61e-01 | -0.1207 |
| 23321 | TRIM2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 3.58e-05 | -5.05e-01 | 0.0528 |
| 23321 | TRIM2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.56e-02 | -2.87e-01 | 0.294 |
| 23321 | TRIM2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.94e-08 | 6.73e-01 | 0.281 |
| 23321 | TRIM2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.14e-05 | -4.08e-01 | 0.3005 |
| 23321 | TRIM2 | A002-C-010 | Human | Colorectum | FAP | 1.57e-05 | 1.49e-01 | 0.242 |
| 23321 | TRIM2 | A015-C-203 | Human | Colorectum | FAP | 9.78e-29 | -2.81e-01 | -0.1294 |
| 23321 | TRIM2 | A014-C-040 | Human | Colorectum | FAP | 2.14e-02 | -2.98e-01 | -0.1184 |
| 23321 | TRIM2 | A002-C-201 | Human | Colorectum | FAP | 1.50e-08 | -2.20e-01 | 0.0324 |
| 23321 | TRIM2 | A001-C-119 | Human | Colorectum | FAP | 4.63e-10 | 2.65e-01 | -0.1557 |
| 23321 | TRIM2 | A001-C-108 | Human | Colorectum | FAP | 3.99e-13 | -1.20e-01 | -0.0272 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001603210 | Cervix | CC | viral process | 109/2311 | 415/18723 | 5.40e-15 | 6.46e-12 | 109 |
| GO:001905810 | Cervix | CC | viral life cycle | 87/2311 | 317/18723 | 2.20e-13 | 1.20e-10 | 87 |
| GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
| GO:005212610 | Cervix | CC | movement in host environment | 52/2311 | 175/18723 | 7.03e-10 | 8.76e-08 | 52 |
| GO:004440910 | Cervix | CC | entry into host | 47/2311 | 151/18723 | 8.45e-10 | 1.03e-07 | 47 |
| GO:005170110 | Cervix | CC | biological process involved in interaction with host | 57/2311 | 203/18723 | 1.18e-09 | 1.41e-07 | 57 |
| GO:004671810 | Cervix | CC | viral entry into host cell | 44/2311 | 144/18723 | 5.47e-09 | 5.03e-07 | 44 |
| GO:004440310 | Cervix | CC | biological process involved in symbiotic interaction | 71/2311 | 290/18723 | 7.94e-09 | 6.98e-07 | 71 |
| GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
| GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
| GO:00002097 | Cervix | CC | protein polyubiquitination | 58/2311 | 236/18723 | 1.57e-07 | 7.41e-06 | 58 |
| GO:00510904 | Cervix | CC | regulation of DNA-binding transcription factor activity | 87/2311 | 440/18723 | 4.85e-06 | 1.22e-04 | 87 |
| GO:007099710 | Cervix | CC | neuron death | 70/2311 | 361/18723 | 7.50e-05 | 1.03e-03 | 70 |
| GO:005079210 | Cervix | CC | regulation of viral process | 38/2311 | 164/18723 | 8.12e-05 | 1.10e-03 | 38 |
| GO:190121410 | Cervix | CC | regulation of neuron death | 61/2311 | 319/18723 | 3.11e-04 | 3.31e-03 | 61 |
| GO:005140210 | Cervix | CC | neuron apoptotic process | 49/2311 | 246/18723 | 4.48e-04 | 4.48e-03 | 49 |
| GO:19001808 | Cervix | CC | regulation of protein localization to nucleus | 31/2311 | 136/18723 | 4.76e-04 | 4.69e-03 | 31 |
| GO:190390010 | Cervix | CC | regulation of viral life cycle | 33/2311 | 148/18723 | 4.86e-04 | 4.76e-03 | 33 |
| GO:00510915 | Cervix | CC | positive regulation of DNA-binding transcription factor activity | 51/2311 | 260/18723 | 5.05e-04 | 4.92e-03 | 51 |
| GO:00523728 | Cervix | CC | modulation by symbiont of entry into host | 15/2311 | 49/18723 | 5.81e-04 | 5.52e-03 | 15 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIM2 | SNV | Missense_Mutation | rs753281036 | c.356N>A | p.Arg119Gln | p.R119Q | Q9C040 | protein_coding | tolerated(0.21) | benign(0.062) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM2 | SNV | Missense_Mutation | novel | c.605G>T | p.Arg202Met | p.R202M | Q9C040 | protein_coding | deleterious(0.04) | probably_damaging(0.984) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM2 | SNV | Missense_Mutation | novel | c.1532G>T | p.Gly511Val | p.G511V | Q9C040 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM2 | SNV | Missense_Mutation | rs777541972 | c.1349N>A | p.Arg450Gln | p.R450Q | Q9C040 | protein_coding | tolerated(0.05) | benign(0.012) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM2 | SNV | Missense_Mutation | novel | c.1306N>A | p.Asp436Asn | p.D436N | Q9C040 | protein_coding | tolerated(0.17) | benign(0.192) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| TRIM2 | SNV | Missense_Mutation | novel | c.1574N>A | p.Gly525Glu | p.G525E | Q9C040 | protein_coding | tolerated(0.06) | probably_damaging(0.977) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| TRIM2 | SNV | Missense_Mutation | novel | c.16N>A | p.Arg6Ser | p.R6S | Q9C040 | protein_coding | deleterious_low_confidence(0) | benign(0.005) | TCGA-PG-A914-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM2 | SNV | Missense_Mutation | novel | c.1328N>A | p.Pro443Gln | p.P443Q | Q9C040 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| TRIM2 | SNV | Missense_Mutation | c.72N>T | p.Gln24His | p.Q24H | Q9C040 | protein_coding | tolerated_low_confidence(0.35) | benign(0.276) | TCGA-44-6774-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | alimta | SD | |
| TRIM2 | SNV | Missense_Mutation | c.623N>G | p.Ser208Cys | p.S208C | Q9C040 | protein_coding | tolerated(0.09) | possibly_damaging(0.635) | TCGA-49-4486-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |